ASST three-lens brief
Evidence-based stock research on ASST. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 11% of its 52-week range — deep in the lower band.
- Trading at 11% of its 52-week range — deep in the lower band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- RSI at 80 — technically overbought.
- Outperforming SPY by 139.3pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
ASST closed at $26.90 (+0.79%) as of 2026-09-11. Market cap: $2.55B. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 139.3pp over 30 days.. Concerns: trading at 11% of its 52-week range — deep in the lower band.; rSI at 80 — technically overbought.. Last quarter: Revenue $2.94M, net income -$283.81M, free cash flow -$455.05M.
Why three lenses on ASST, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ASSTacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ASST" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ASST brief"></iframe>